Incyte Corporation (NASDAQ: INCY) is shifting its strategy to focus on expanding its non-JAKAFI business and developing late-stage clinical programs as it prepares for the loss of exclusivity for JAKAFI in 2029. CEO Bill Meury reported that the company’s core business is currently generating around $2 billion in sales, with a goal to increase this to $3 billion to $4 billion by 2030, anticipating a 15% to 20% annual growth rate from 2030 to 2035 if pipeline programs are successful.
The company expects that extended-release JAKAFI XR will achieve formulary coverage of 70% to 80% by year-end. Meury noted that 10% to 30% of JAKAFI patients could transition to XR, which might protect nearly $750 million in sales during the exclusivity transition. Incyte also has several clinical trials in progress, including pivotal studies for its CALR antibody in myelofibrosis and essential thrombocythemia, as well as promising developments in solid tumor therapies, particularly a KRAS G12D inhibitor in pancreatic cancer.
The firm’s recent acquisition of Vega Therapeutics aims to enhance its offerings in hematology, particularly with a new treatment for von Willebrand disease, which could significantly expand patient access as only about 2,000 of an estimated 30,000 eligible patients currently receive prophylaxis. Incyte’s robust research and development agenda, including upcoming data presentations, highlight its commitment to innovative oncology and inflammatory disease therapies.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
